The Global Hemato Oncology Testing Market was valued at $2.2 Billion in 2020. Growing at a high CAGR of more than 13.3% between 2021 and 2031, it is estimated to reach $8.9 Billion by 2031. However, the current pandemic of COVID-19 might make a slight difference in the growth rate in the present year. Hemato oncology testing is the science associated with the diagnosis, treatment, and prevention of blood-related diseases and cancers. The increasing prevalence of myeloma and lymphoma is anticipated to propel the market's growth during the forecast period. In addition to this, increasing conferences on personalized medicines, the rising collaboration between manufacturer, and growing demand for advanced treatment options are the factors which drive the market during the forecast period. Now, moving forward, the robust demand for the global Hemato Oncology Testing market in the healthcare department is further estimated to create new necessities and augment the market of growth over the forecast period of 2021-2031.
Global Hemato Oncology Testing Segment Is Estimated to Witness Remarkable Growth
Source: SAI Research
The Hemato Oncology Testing market is segmented as cancer type, product, technology, and end-use. Based on Cancer Type the global Hemato Oncology Testing Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphocytic market is divided into Leukemia (ALL), Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloproliferative Neoplasms, Polycythemia vera (PV), Essential thrombocythemia (ET), Myelofibrosis (MF), and Other Cancers. Based on Product, the global Hemato Oncology Testing market has been bifurcated as Assay Kits and Reagents, and Services. Based on Technology, the global Hemato Oncology Testing market is segmented as PCR, Real-time qPCR, Digital PCR, IHC, NGS, Cytogenetics, and Other Technologies. Based on End-Use, the global Hemato Oncology Testing market has been bifurcated as Hospitals, Academic & Research Institutes, and Others.
By Region, North America is Holding the Major Market Share
The Hemato Oncology Testing Market has been geographically segmented into North America, Asia Pacific, Latin America, Middle East, Europe, and Africa region. In addition to this, North America has a significant share among those regions. The growing demand for oncology testing and increasing investment are the factors in the development of the market. Increasing disposal incomes, availability of advanced technology, skilled manpower, and other potential factors drive the market over the forecast period. Apart from that, the Asia Pacific and the Rest of the regions are expected to increase the growth rate in the upcoming forecast period of 2021 to 2031.
Major Players in the Global Hemato Oncology Testing Market
The report covers a detailed outlook about the company, and it includes the company or industry profiles and market share of key players operating in the global market. Key players in the report include F. Hoffman-La Roche Ltd, Abbott Laboratories, EntroGen, Inc., Qiagen N.V., Cepheid, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Amoy Diagnostics Co. Ltd., Asuragen, Inc. ArcherDX, Inc, Invivoscribe, Inc., Adaptive Biotechnologies, ARUP Laboratories, and ICON Specialty Laboratories among others.
The Global Hemato Oncology Testing Market Has Been Segmented into:
Global Hemato Oncology Testing Market: By Cancer Type
Global Hemato Oncology Testing Market: By Product
Global Hemato Oncology Testing Market: By Technology
Global Hemato Oncology Testing Market: By End-Use
Global Hemato Oncology Testing Market: By Region